000285003 001__ 285003
000285003 005__ 20260202112928.0
000285003 0247_ $$2doi$$a10.1007/s00259-025-07579-3
000285003 0247_ $$2pmid$$apmid:41114734
000285003 0247_ $$2ISSN$$a1619-7070
000285003 0247_ $$2ISSN$$a1619-7089
000285003 037__ $$aDZNE-2026-00137
000285003 041__ $$aEnglish
000285003 082__ $$a610
000285003 1001_ $$aCrook, Harry$$b0
000285003 245__ $$aComparing and combining TSPO-PET tracers in tauopathies.
000285003 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2026
000285003 3367_ $$2DRIVER$$aarticle
000285003 3367_ $$2DataCite$$aOutput Types/Journal article
000285003 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770027558_15532
000285003 3367_ $$2BibTeX$$aARTICLE
000285003 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285003 3367_ $$00$$2EndNote$$aJournal Article
000285003 520__ $$aNeuroinflammation is a key pathological driver in neurodegenerative diseases, including Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP). Positron emission tomography (PET) with tracers targeting the translocator protein (TSPO) enables the in vivo quantification of microgliosis. TSPO tracers have shown similar disease-specific patterns across cohorts. However, direct quantitative comparisons between commonly used TSPO-PET tracers in tauopathies have not been performed. Here, we apply a TSPO-PET standardization pipeline across clinically matched AD cohorts and PSP cohorts, to quantify, compare and combine multi-centre TSPO-PET data.Patients with PSP were scanned with either [11C]PK11195 or [18F]GE-180 at one of two centres, while patients with AD and control participants were scanned with either [11C]PK11195, [18F]GE-180 or [11C]PBR28 at one of three centres. A standardised pre-processing pipeline was implemented and participant standardised uptake volume ratio (SUVR) values were z-scored using tracer-specific control participant values. In a data-driven approach, dissimilarity analyses were employed to assess differences between tracers across clinically matched cohorts.In PSP, dissimilarity analysis suggested that [11C]PK11195 and [18F]GE-180 binding patterns were comparable following standardisation. In AD, comparability across tracers was less robust, with [11C]PK11195 and [18F]GE-180 being most comparable, followed by [18F]GE-180 vs. [11C]PBR28, then by [11C]PK11195 vs. [11C]PBR28.The pipeline was effective at harmonising TSPO-PET tracers and standardising the regional quantification of neuroinflammation in clinically matched cohorts of PSP, while the standardisation pipeline results were less robust across AD cohorts.
000285003 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285003 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000285003 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285003 650_7 $$2Other$$aAlzheimer’s disease.
000285003 650_7 $$2Other$$aNeuroinflammation
000285003 650_7 $$2Other$$aPositron emission tomography
000285003 650_7 $$2Other$$aProgressive supranuclear palsy
000285003 650_7 $$2Other$$aTranslocator protein
000285003 650_7 $$2NLM Chemicals$$aReceptors, GABA
000285003 650_7 $$2NLM Chemicals$$aTSPO protein, human
000285003 650_7 $$2NLM Chemicals$$aRadioactive Tracers
000285003 650_7 $$0YNF83VN1RL$$2NLM Chemicals$$aPK 11195
000285003 650_7 $$2NLM Chemicals$$aGE-180
000285003 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000285003 650_7 $$2NLM Chemicals$$aCarbazoles
000285003 650_7 $$2NLM Chemicals$$aIsoquinolines
000285003 650_2 $$2MeSH$$aHumans
000285003 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000285003 650_2 $$2MeSH$$aPositron-Emission Tomography: standards
000285003 650_2 $$2MeSH$$aReceptors, GABA: metabolism
000285003 650_2 $$2MeSH$$aMale
000285003 650_2 $$2MeSH$$aFemale
000285003 650_2 $$2MeSH$$aAged
000285003 650_2 $$2MeSH$$aMiddle Aged
000285003 650_2 $$2MeSH$$aRadioactive Tracers
000285003 650_2 $$2MeSH$$aTauopathies: diagnostic imaging
000285003 650_2 $$2MeSH$$aTauopathies: metabolism
000285003 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000285003 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000285003 650_2 $$2MeSH$$aRadiopharmaceuticals
000285003 650_2 $$2MeSH$$aCarbazoles
000285003 650_2 $$2MeSH$$aIsoquinolines
000285003 7001_ $$aFranzmeier, Nicolai$$b1
000285003 7001_ $$aRahmouni, Nesrine$$b2
000285003 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b3$$udzne
000285003 7001_ $$aFryer, Tim D$$b4
000285003 7001_ $$aHong, Young T$$b5
000285003 7001_ $$aRoemer-Cassiano, Sebastian N$$b6
000285003 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b7$$udzne
000285003 7001_ $$aStrauss, Alexandra$$b8
000285003 7001_ $$aJones, P Simon$$b9
000285003 7001_ $$aAigbirhio, Franklin I$$b10
000285003 7001_ $$aHopewell, Robert$$b11
000285003 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b12$$udzne
000285003 7001_ $$aMassarweh, Gassan$$b13
000285003 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b14$$udzne
000285003 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b15$$udzne
000285003 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b16$$udzne
000285003 7001_ $$aRowe, James B$$b17
000285003 7001_ $$aO'Brien, John T$$b18
000285003 7001_ $$aRosa-Neto, Pedro$$b19
000285003 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b20$$udzne
000285003 7001_ $$00000-0001-8923-9656$$aMalpetti, Maura$$b21
000285003 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07579-3$$gVol. 53, no. 3, p. 2083 - 2098$$n3$$p2083 - 2098$$tEuropean journal of nuclear medicine and molecular imaging$$v53$$x1619-7070$$y2026
000285003 8564_ $$uhttps://pub.dzne.de/record/285003/files/DZNE-2026-00137.pdf$$yRestricted
000285003 8564_ $$uhttps://pub.dzne.de/record/285003/files/DZNE-2026-00137.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285003 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b3$$kExtern
000285003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285003 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b12$$kExtern
000285003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000285003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000285003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000285003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000285003 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285003 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000285003 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-07$$wger
000285003 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-07$$wger
000285003 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-07
000285003 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2025-11-07
000285003 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000285003 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x1
000285003 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000285003 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x3
000285003 980__ $$ajournal
000285003 980__ $$aEDITORS
000285003 980__ $$aVDBINPRINT
000285003 980__ $$aI:(DE-2719)1111015
000285003 980__ $$aI:(DE-2719)5000022
000285003 980__ $$aI:(DE-2719)1111016
000285003 980__ $$aI:(DE-2719)1110007
000285003 980__ $$aUNRESTRICTED